Compare BridgeBio Pharma Inc (BBIO) vs iShares Core S&P 500 ETF (IVV) Price & Performance

BridgeBio Pharma IncTrade

iShares Core S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs iShares Core S&P 500 ETF — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while iShares Core S&P 500 ETF trades at $756.88. Which is the better fit depends on your goals.

	BBIO	IVV
Market Cap	$16.46B	—
Sector	Health	Broad Market / Factor
52-Week High	$90.17	$763.10
52-Week Low	$44.81	$624.65
Enterprise Value	$18.02B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

iShares Core S&P 500 ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BBIO

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.Seeking Alpha · 3 days agoBullish View details →

IVV

Invesco S&P 500 Equal Weight ETF underperforms cheaper cap-weighted funds due to fees, cash drag, and rebalancing costs.24/7 Wall Street · 1 day agoBearish Markets hit highs amid historic overvaluation and record margin debt in H1 2026, signaling caution ahead.ETF Trends · 1 day agoNeutral S&P 500 nears record high with 1.3% weekly gain, up 10.7% YTD in 2026.ETF Trends · 4 days agoNeutral View details →

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.